Loading stock data…
SOPH
$5.29-0.03 (-0.56%)
Market ClosedLast close May 4
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SOPHiA GENETICS SA in the Healthcare sector is trading at $5.29. The stock is currently near its 52-week high of $5.70, remaining 20.2% above its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why SOPH maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.29
Potential Upside
5%
Whystock Fair Value$5.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic mod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$361.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-155.68%
Volume
Today's trading volume
42,245
Recent News
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
How The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value Targets
The analyst price target on SOPHiA GENETICS has been revised to $8.00, up from $7.67, reflecting an updated view of what the shares could be worth under current modeling assumptions. Recent commentary links this shift to refreshed fair value work that leans on revised inputs, while highlighting both optimism around execution and caution about what still needs to fall into place. As you read on, you will see how these evolving targets can help you track the story and understand what to watch...
What's Driving TEM Data and Applications Arm's Robust Growth?
Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.
How The SOPHiA GENETICS (SOPH) Narrative Is Shifting With Recalibrated Growth And Valuation Assumptions
SOPHiA GENETICS is back in focus after analysts reset their price target at $7.67, holding it steady between the prior and updated assessment. Bulls read this as the stock better reflecting their expectations for stronger revenue growth, while bears highlight that the roughly $1 shift still points to a fairly limited change in implied upside. As you read on, you will see how both sides are updating their views and what to watch as this narrative continues to evolve. Analyst Price Targets...
Sophia Genetics SA (SOPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Sophia Genetics SA (SOPH) reports a 22% increase in Q4 revenue, expands customer base, and outlines strategic growth plans for 2026.